



(51) International Patent Classification:

C07D 239/48 (2006.01) **C07D 491/056** (2006.01)
C07D 401/04 (2006.01) **C07D 491/20** (2006.01)
C07D 401/14 (2006.01) **C07D 498/08** (2006.01)
C07D 403/04 (2006.01) **C07D 519/00** (2006.01)
C07D 405/14 (2006.01) **A61K 31/53** (2006.01)
C07D 413/14 (2006.01) **A61K 31/506** (2006.01)
C07D 491/048 (2006.01) **A61P 35/00** (2006.01)

(21) International Application Number:

PCT/EP2015/076192

(22) International Filing Date:

10 November 2015 (10.11.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

14192617.0 11 November 2014 (11.11.2014) EP

(71) Applicants: **PIQUR THERAPEUTICS AG** [CH/CH];
Hochbergerstrasse 60c, CH-4057 Basel (CH). **UNI-
VERSITÄT BASEL** [CH/CH]; Vizerektorat Forschung,
Petersgraben 35, CH-4003 Basel (CH).

(72) Inventors: **CMILJANOVIC, Vladimir**; Hohe Winde
Strasse 120, CH-4059 Basel (CH). **HEBEISEN, Paul**; St.
Albanring 184, CH-4052 Basel (CH). **BEAUFILS,
Florent**; 28 rue des ecureuils, F-68870 Bartenheim (FR).
BOHNACKER, Thomas; Vogesenstrasse 65, CH-4056
Basel (CH). **RAGEOT, Denise**; 18 rue de la tuilerie, F-
68300 Saint-Louis (FR). **SELE, Alexander**; Amerbach-
strasse 86, CH-4057 Basel (CH). **WYMANN, Matthias**;
Bühlstrasse 44, CH-3012 Bern (CH). **LANGLOIS, Jean-
Baptiste**; 23 rue des tisserands, F-68510 Sierentz (FR).

(74) Agent: **SPERRLE, Martin**; Latscha Schöllhorn Partner
AG, Austrasse 24, CH-4051 Basel (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES



(57) Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR) and PI3K-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X¹, X² and X³ are N or CH, with the proviso that at least two of X¹, X² and X³ are N; Y is N or CH. These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.